Pharmaco-toxicity of vehicles in drug therapy for Parkinson disease
Keywords:
Pharmacotoxicity, Parkinson disease, nanotechnology, carriers, drugAbstract
Drug treatment for neurodegenerative disorders such as Parkinsonism, are intended to im-
prove or moderate symptoms in spite of their potential systemic toxic effects. Pharmaceutical
nanotechnology focusing on vehiculization of drugs was expected to improve effectiveness on
drug administration. However body responses have not always resulted as expected, since the
hemato-encephalic barrier still plays her roll on drug transportation. Detoxification process of
drugs and their vehicles can modify the expected clinical response to treatment. A hope arises
to drug transportation, either by vehicles or by loaded cells with nanoparticles into specific
targets through the central nervous system with no significant loss of power or systemic toxicity.
Mechanisms of cell-drug transportation are still unsolved, even more to focus on cell tropism into
specific targets since cells are exposed to a variety of stimuli capable to modify their direction,
metabolism or even death by apoptosis.
Publication Facts
Reviewer profiles N/A
Author statements
Indexed in
- Editor & editorial board
- profiles
- Academic society
- N/A
To learn about these publication facts, click 
PF is maintained by the Public Knowledge Project
References
Connolly BS, Lang AE. Pharmacological treatment of Par-
kinson disease: a review. JAMA. 2014; 311 (16): 1670-1683.
Kim SN, Doo AR, Park JY, Choo HJ, Shim I, Park JJ
et al. Combined treatment with acupuncture reduces
effective dose and alleviates adverse effect of L-dopa by
normalizing Parkinson’s disease-induced neurochemica
limbalance. Brain Res. 2014; 1544: 33-44.
Fernández M, Barcia E, Fernández-Carballido A, Garcia
L, Slowing K, Negro S. Controlled release of rasagiline
mesylate promotes neuroprotection in a rotenone-
induced advanced model of Parkinson’s disease. Int J
Pharm. 2012; 438 (1-2): 266-278.
Fernández M, Negro S, Slowing K, Fernández-Carba-
llido A, Barcia E. An effective novel delivery strategy of
rasagiline for Parkinson’s disease. Int J Pharm. 2011;
(1-2): 271-280.
Giordano C, Albani D, Gloria A, Tunesi M, Rodilossi S,
Russo T et al. Nanocomposites for neurodegenerative
diseases: hydrogel-nanoparticle combinations for a
challenging drug delivery. Int J Artif Organs. 2011; 34
(12): 1115-1127.
Li T, Shi T, Li X, Zeng S, Yin L, Pu Y. Effects of nano-
MnO2 on dopaminergic neurons and the spatial learning
capability of rats. Int J Environ Res Public Health. 2014;
(8): 7918-7930.
Fernandes C, Soni U, Patravale V. Nano-interventions
for neurodegenerative disorders. Pharmacol Res. 2010;
(2): 166-178.
Jain V, Jain S, Mahajan SC. Nanomedicines based drug
delivery systems for anti-cancer targeting and treatment.
Curr Drug Deliv. 2014; Aug 22. En prensa.
Elsaesser A, Howard CV. Toxicology of nanoparticles.
Adv Drug Deliv Rev. 2012; 64 (2): 129-137.
Hwang SR, Kim K. Nano-enabled delivery systems
across the blood-brain barrier. Arch Pharm Res. 2014;
(1): 24-30.
Alam MI, Beg S, Samad A, Baboota S, Kohli K, Ali J et
al. Strategy for effective brain drug delivery. Eur J Pharm
Sci. 2010; 40 (5): 385-403.
Modi G, Pillay V, Choonara YE, Ndesendo VM, du Toit
LC, Naidoo D. Nanotechnological applications for the
treatment of neurodegenerative disorders. Prog Neuro-
biol. 2009; 88 (4): 272-285.
Walkey CD, Chan WC. Understanding and controlling
the interaction of nanomaterials with proteins in a phy-
siological environment. Chem Soc Rev. 2012; 41 (7):
-2799.
Nowacek A, Kosloski LM, Gendelman HE. Neurodege-
nerative disorders and nano formulated drug develop-
ment. Nanomedicine (Lond). 2009; 4 (5): 541-555.
Verhoef JJ, Carpenter JF, Anchordoquy TJ, Schelle-
kens H. Potential induction of anti-PEG antibodies and
complement activation toward PEGyla ted therapeutics.
Drug Discov Today. 2014. pii: S1359-6446(14)00342-0.
En prensa.
O’Loughlin AJ, Woffi ndale CA, Wood MJ. Exosomes
and the emerging fi eld of exosome-based gene therapy.
Curr Gene Ther. 2012; 12 (4): 262-274.
Brynskikh AM, Zhao Y, Mosley RL, Li S, Boska MD,
Klyachko NL et al. Macrophage delivery of therapeutic
nanozymes in a murine model of Parkinson’s disease.
Nanomedicine (Lond). 2010; 5 (3): 379-396.
Arora P, Sindhu A, Dilbaghi N, Chaudhury A, Rajakumar
G, Rahuman AA. Nano-regenerative medicine towards
clinical outcome of stem cell and tissue engineering in
humans. J Cell Mol Med. 2012; 16 (9): 1991-2000.
Bose T, Latawiec D, Pratim MP, Mandal S. Overview
of nano-drugs characteristics for clinical application: the
journey from the entry to the exit point. J Nanopart Res.
; 16: 2527.
Pehlivan SB. Nanotechnology-based drug delivery
systems for targeting, imaging and diagnosis of neu-
rodegenerative diseases. Pharm Res. 2013; 30 (10):
-2511.
Li Y, Zhang Y, Yan B. Nanotoxicity overview: nano-threat
to susceptible populations. Int J Mol Sci. 2014; 15 (3):
-3697.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra
This work is licensed under a Creative Commons Attribution 4.0 International License.
© Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra under a Creative Commons Attribution 4.0 International (CC BY 4.0) license which allows to reproduce and modify the content if appropiate recognition to the original source is given.
